3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
7
Terminated
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Conditions
Uterine Cervical Neoplasms
1
Interventions
pembrolizumab
45
Paclitaxel
45
Carboplatin
39
Magnetic Resonance Spectroscopy
28
olaparib
27
Specimen Handling
26
Cisplatin
24
Bevacizumab
20
Nivolumab
18
Taxes
17
Biopsy
16
Gemcitabine
13
Cyclophosphamide
13
durvalumab
12
Immunoglobulin G
11
Doxorubicin
11
Disulfides
11
Surveys and Questionnaires
10
niraparib
9
liposomal doxorubicin
9
dostarlimab
9
Radiotherapy
8
Brachytherapy
8
lenvatinib
7
fludarabine
7
atezolizumab
7
Letrozole
7
Docetaxel
7
cediranib
6
Platinum
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
tisotumab vedotin
×
Gynecologic
×
Clear all
NCT06459180
2026-05-27
TroFuse-020
Merck Sharp & Dohme LLC
Phase 3
Active not recruiting
686 enrolled